SCYNEXIS Inc
NASDAQ:SCYX
Net Margin
SCYNEXIS Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
SCYNEXIS Inc
NASDAQ:SCYX
|
27.4m USD |
-1 030%
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
751.6B USD |
23%
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
-4%
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
377.4B USD |
24%
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.9T DKK |
35%
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
204.3B CHF |
14%
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
188.5B CHF |
24%
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
162B GBP |
14%
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
209.7B USD |
27%
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
184.8B USD |
-126%
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
13%
|
SCYNEXIS Inc
Glance View
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company is headquartered in Jersey City, New Jersey and currently employs 56 full-time employees. The company went IPO on 2014-05-02. The firm is developing its lead product candidate, ibrexafungerp, as a broad-spectrum, intravenous (IV)/oral agent for multiple fungal indications in both the community and hospital settings. The company has received the approval from the United States Food and Drug Administration (FDA) for the New Drug Application (NDA) for BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC, also known as vaginal yeast infection). BREXAFEMME is a triterpenoid antifungal indicated for the treatment of adult and postmenarchal pediatric females with vulvovaginal candidiasis (VVC). The company is also continuing late-stage clinical development of ibrexafungerp for multiple indications, including the treatment of life-threatening invasive fungal infections in hospitalized patients.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on SCYNEXIS Inc's most recent financial statements, the company has Net Margin of -1 030%.
You don't have any saved screeners yet